Get the Stockscreener App
2.28
5.00%
-0.12
Humacyte Inc stock is traded at $2.28, with a volume of 5.79M.
It is down -5.00% in the last 24 hours and up +0.00% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$2.40
Open:
$2.2
24h Volume:
5.79M
Relative Volume:
1.43
Market Cap:
$353.67M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-2.1308
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
-9.88%
1M Performance:
+0.00%
6M Performance:
-50.22%
1Y Performance:
-73.55%
1-Day Range:
$2.19
$2.31
1-Week Range:
$2.19
$2.65
52-Week Range:
$1.15
$8.7187
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
2.28 | 372.29M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
What is the dividend policy of Humacyte Inc. stockFinancial News Tips To Watch Now - jammulinksnews.com
What are Humacyte Inc. Equity Warrant company’s key revenue driversAdvanced Screener Planner For 2025 - jammulinksnews.com
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights - MSN
How does Humacyte Inc. Equity Warrant compare to its industry peersAI Powered Updates From AI Tools - jammulinksnews.com
Measuring Humacyte Inc.’s beta against major indicesAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire
Humacyte, Inc. (NASDAQ:HUMA): Is Breakeven Near? - Yahoo Finance
Is Humacyte Inc. Equity Warrant in Accumulation Phase NowWealth Building Stock Market Ideas Based on Momentum - metal.it
What institutional investors are buying Humacyte Inc. Equity Warrant stockStock Market Entry Points To Watch Now - jammulinksnews.com
Why is Humacyte Inc. stock attracting strong analyst attentionBest Dividend Picks For 2025 - jammulinksnews.com
Is Humacyte Inc. a growth stock or a value stockMaximize your returns with smart trade entries - jammulinksnews.com
How does Humacyte Inc. compare to its industry peersMaximize returns with disciplined investment techniques - jammulinksnews.com
When is Humacyte Inc. stock expected to show significant growthAchieve rapid capital gains with smart investing - jammulinksnews.com
What makes Humacyte Inc. stock price move sharplyTriple-digit returns - jammulinksnews.com
How strong is Humacyte Inc. Equity Warrant company’s balance sheetAchieve rapid portfolio appreciation today - jammulinksnews.com
What markets is Humacyte Inc. expanding into Is WTRG stock a good long term investment optionMassive portfolio appreciation - jammulinksnews.com
Does Humacyte Inc. Equity Warrant stock perform well during market downturnsMaximize portfolio returns with smart trading - jammulinksnews.com
When is Humacyte Inc. Equity Warrant stock expected to show significant growthSkyrocketing investment returns - jammulinksnews.com
Should I hold or sell Humacyte Inc. stock in 2025Maximize your portfolio’s growth potential - jammulinksnews.com
What are Humacyte Inc. company’s key revenue driversInvest confidently with professional market insights - jammulinksnews.com
What catalysts could drive Humacyte Inc. Equity Warrant stock higher in 2025Market-leading growth rates - jammulinksnews.com
How does Humacyte Inc. generate profit in a changing economyUnlock exclusive stock market insights - jammulinksnews.com
What institutional investors are buying Humacyte Inc. stockCapitalize on market momentum for maximum profit - jammulinksnews.com
Why is Humacyte Inc. Equity Warrant stock attracting strong analyst attentionMaximize your gains with expert trading tips - jammulinksnews.com
Is Humacyte Inc. stock overvalued or undervaluedMaximize your gains with professional insights - jammulinksnews.com
Humacyte Inc. Stock Analysis and ForecastExplosive trading opportunities - PrintWeekIndia
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
What drives Humacyte Inc. stock priceExceptional return forecasts - PrintWeekIndia
Humacyte Inc. Equity Warrant Stock Analysis and ForecastDynamic profit expansion - PrintWeekIndia
What analysts say about Humacyte Inc. Equity Warrant stockOutstanding investment returns - PrintWeekIndia
Will Humacyte Inc. Equity Warrant stock benefit from AI tech trendsBreakout stock performance - jammulinksnews.com
What analysts say about Humacyte Inc. stockExceptional risk-adjusted gains - PrintWeekIndia
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):